Sanofi Expected to Report Higher Sales; Capital ... - MarketWatch
2 days ago · Sanofi is likely to implement a buyback, Jefferies analysts said a note. ... Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional ...
Latest Sanofi Press Releases and News | Sanofi
Sep 26, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi reaches deal on terms of sale of consumer health arm, say …
4 days ago · SNY. PARIS (Reuters) -Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R ...
Sanofi: Bankers Do Anything It Takes to Grab a Piece of Rare …
21 hours ago · CD&R this week entered exclusive talks with drugmaker Sanofi to buy half of its consumer arm, Opella. Getting burned on Morrisons back in 2022 hasn’t stopped a horde of banks from fighting to ...
Live news: Sanofi enters exclusive talks on €16bn consumer …
5 days ago · Sanofi enters exclusive talks on €16bn consumer health sale. France’s Sanofi is pursuing an offer from US private equity group Clayton, Dubilier & Rice for control of its consumer healthcare ...
Sanofi US News
Sep 27, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi pushes ahead with €20bn consumer healthcare spin-off
Jun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Press Room - Sanofi US News
Oct 16, 2024 · FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals. Read more.
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best ...
Jan 23, 2006 · Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline. Acquisition supports Sanofi’s portfolio growth strategy and complements 30-year heritage in rare diseases and proven industry leadership in immunology and inflammation. For each Inhibrx share, Inhibrx shareholders ...
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
Dec 7, 2002 · Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.